Inhibikase Therapeutics, Inc.
IKT
$1.44
$0.032.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -143.58% | -125.79% | -90.35% | -44.62% | -2.27% |
| Total Depreciation and Amortization | 154.55% | 89.77% | -81.84% | -85.12% | -84.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6,263.35% | 5,377.67% | 3,434.39% | 1,431.05% | -22.35% |
| Change in Net Operating Assets | -176.93% | -7.27% | -68.59% | -12.65% | 586.66% |
| Cash from Operations | -48.54% | -20.86% | -21.31% | -5.88% | 5.24% |
| Capital Expenditure | -- | -- | 5.63% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -10,119.60% | -137.56% | -188.92% | -417.06% | -101.91% |
| Cash from Investing | -10,123.35% | -137.65% | -189.10% | -417.45% | -101.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,535.08% | 2,665.89% | 25,786.51% | 1,106.09% | -55.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -177.85% | -- | 118.09% | 100.00% | -- |
| Cash from Financing | 2,624.40% | 2,776.18% | 53,325.28% | 1,131.15% | -57.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 367.83% | 6,219.31% | 4,534.14% | 2,294.17% | -253.62% |